Announced Thu, 23 Jul · 16:44 IST
Board meeting on Aug 7 to consider Q1 FY27 results and AGM extension
Results View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.3%1-day move
₹2.99
prior close
₹2.91
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+0.3—————————
Up moveDown movePending
AI summary
Transgene Biotek's board will meet on August 7, 2026 to approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the limited review report. The board will also consider seeking an extension of time for holding the AGM for FY26 and appoint an internal auditor for FY27. The trading window has been closed since July 1, 2026 until 48 hours after the results are made public.
Likely market impact
Investors should watch for Q1 FY27 results on August 7. Seeking an AGM extension could be a minor governance red flag worth monitoring.